A Q&A with Dr. Ganesh Bala on LC–MS and Multi-Attribute Methods for Bioconjugate CQA Monitoring
Agilent’s Dr. Ganesh Bala explained that multi‑attribute methods (MAMs) using LC‑MS peptide mapping have become a core analytical platform for monitoring critical quality attributes of antibody‑drug conjugates (ADCs) and other bioconjugates. He highlighted the growing heterogeneity of these molecules—variable conjugation sites, drug‑to‑antibody ratios, and new degradation pathways—requiring site‑specific, quantitative assays that still maintain high throughput. By consolidating multiple tests into a single workflow, MAMs deliver faster, more consistent data that supports development decisions and regulatory filings. The approach is now viewed as a foundational, not exploratory, tool for the industry.
Teva Launches Ahzantive Aflibercept Biosimilar for Retinal Diseases in Europe
Teva Pharmaceutical Industries has launched Ahzantive, an EMA‑approved aflibercept biosimilar, in France, Germany, Spain and the Netherlands as of May 2026. The product mirrors Eylea for wet age‑related macular degeneration, diabetic macular edema, myopic choroidal neovascularisation and macular edema secondary to...
The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy
Eli Lilly has signed a licensing deal with Ascidian Therapeutics to use its RNA exon‑editing platform for inherited kidney diseases, underscoring the rise of reversible RNA‑based medicines. Tenaya Therapeutics presented interim results for its TN‑201 gene‑therapy, showing cardiac remodeling and lowered...
Basel Innovation Park Main Campus Expands Flexible Infrastructure for Biopharma Startups and Manufacturing
Switzerland Innovation Park’s Basel Main Campus has unveiled a flexible, GMP‑ready laboratory and pre‑production infrastructure aimed at biopharma startups and scale‑up manufacturers. The modular facilities, backed by multi‑million‑dollar investments, allow companies to conduct early‑stage research, test manufacturing processes, and generate...
Tailoring Strategies to APAC’s Diverse Clinical Trial Environment
APAC is emerging as a strategic hub for clinical trials, but its regulatory, operational, and cultural diversity requires tailored sponsor strategies. Countries such as Australia and New Zealand offer streamlined early‑phase pathways, while China and India deliver large patient pools for...
Is Your Annex 1 Strategy a Static Document or a Dynamic Defense?
The 2023 revision of the EU GMP Annex 1 transforms sterile‑manufacturing oversight from prescriptive checklists to a performance‑based, risk‑driven contamination control strategy (CCS). Regulators now require sponsors to demonstrate how sterility assurance is designed, governed, monitored, and continuously improved across a...
Biohub Open-Source AI Model Targets Protein Design for Drug Discovery
Biohub, part of the Chan Zuckerberg Initiative, launched an open‑source AI system that models protein biology at evolutionary scale to aid early‑stage drug discovery. The platform, described as a “world model,” was used to design protein binders targeting cancer and...
Small Molecules to Complex Biologics: Mastering Bioanalytical Workflows Using High Resolution Mass Spectrometry (HRMS)
A webinar hosted by Meadowhawk Biolabs will showcase how high‑resolution mass spectrometry (HRMS), specifically the SCIEX ZenoTOF 7600+, can bridge the analytical gap between small polar metabolites and large‑molecule biologics such as antibody‑drug conjugates (ADCs). Real‑world case studies will demonstrate targeted...
Jade Biosciences Initiates First-in-Human Phase 1 Trial of BAFF-R Antibody JADE201
Jade Biosciences has dosed the first participant in a first‑in‑human Phase 1 trial of JADE201, an investigational half‑life‑extended afucosylated anti‑BAFF‑R monoclonal antibody. The randomized, placebo‑controlled study evaluates single ascending doses in rheumatoid arthritis patients, focusing on safety, tolerability, pharmacokinetics and pharmacodynamics....
Olezarsen Cuts Pancreatitis Events in Severe Hypertriglyceridemia Analysis
Swedish Orphan Biovitrum (Sobi) presented a pooled analysis of its phase 3 CORE and CORE2 trials showing that the RNA‑targeted drug olezarsen reduced acute pancreatitis events by 85% and lowered triglycerides up to 66% in patients with severe hypertriglyceridemia (baseline ≥880 mg/dL)....
The BioPharm Brief: Oncology, Growth, Validation
Kelun‑Biotech announced that its antibody‑drug conjugate sac‑TMT achieved a statistically significant improvement in progression‑free survival versus chemotherapy in a Phase 3 trial for first‑line metastatic triple‑negative breast cancer. BioMarin reported that its growth‑hormone analog vosoritide met the primary endpoint in a...
The BioPharm Brief: Weight Loss, Oncology, Longevity
Merck has moved its antibody‑drug conjugate (ADC) targeting metastatic colorectal cancer into a Phase 3 trial, underscoring the growing confidence in precision oncology. Eli Lilly reported that its multi‑receptor obesity drug retatrutide achieved up to 28.3% weight loss in a pivotal Phase 3...
Site-Centered Startup: Approaching Predictability in an Imperfect System
Study start‑up continues to be hampered by complex protocols, lengthy negotiations, and fragmented communication. ICON’s executive vice president Brian Mallon argues that a site‑centered model—integrating early feasibility with real‑world capacity, sustained momentum, and automation—can transform activation from an imperfect science...
Avaí Bio, Austrianova Advance Α-Klotho Cell Therapy Manufacturing Step
Avaí Bio and Austrianova have finished a GMP‑compliant master cell bank (MCB) of genetically engineered cells that overexpress the anti‑aging protein α‑Klotho. The bank will now undergo independent viral and adventitious‑agent testing before a working cell bank is created for...
Advanced LC-MS Technology for Enhanced HCP Detection in Complex Biotherapeutics
Advanced liquid chromatography‑mass spectrometry (LC‑MS) techniques are now being integrated into biopharmaceutical manufacturing to more accurately identify, characterize, and quantify host cell protein (HCP) impurities. The new workflows achieve sub‑parts‑per‑million detection limits, enabling manufacturers to mitigate contamination risks earlier in...
The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains
Wave Life Sciences reported that its RNA‑editing candidate WVE‑006 achieved protein levels comparable to the milder MZ‑like phenotype in a Phase 1b/2a trial for alpha‑1 antitrypsin deficiency, suggesting a potential disease‑modifying effect. Novo Nordisk presented new semaglutide data from the ESSENCE...
WVE-006 RNA Editing Therapy Achieves MZ-Like Phenotype in Alpha-1 Antitrypsin Deficiency Phase 1b/2a Trial
Wave Life Sciences reported that its investigational RNA‑editing drug WVE‑006 generated major‑variant alpha‑1 antitrypsin (M‑AAT) levels comparable to the protective heterozygous Pi*MZ phenotype in patients with homozygous Pi*ZZ AAT deficiency. The Phase 1b/2a RestorAATion‑2 trial showed 64%–59% of circulating AAT was...
The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration
Biopharma firms are accelerating the adoption of next‑generation platforms to boost therapeutic precision and speed. JCR Pharmaceuticals unveiled preclinical data for its JUST‑AAV system, which enhances central nervous system delivery while limiting liver exposure. Hansa Biopharma signed a deal worth...
Why the Need to Expand Industry Focus Beyond Gene Editing Toward Scalable Cell Therapy Manufacturing?
Cell therapy developers are moving beyond pure gene‑editing breakthroughs to prioritize scalable manufacturing, according to Cellular Origins CEO Dr. Edwin Stone at the 2026 ASGCT meeting. The industry is integrating manufacturing feasibility into early‑stage development, evaluating multiple delivery platforms such...
JCR Pharmaceuticals Highlights Preclinical CNS Gene Therapy Data for JUST-AAV Platform at ASGCT 2026
JCR Pharmaceuticals showcased preclinical data for its JUST‑AAV platform at ASGCT 2026, highlighting enhanced central nervous system (CNS) delivery and reduced liver exposure compared with conventional AAV9 vectors. The platform uses transferrin‑receptor‑targeted capsids to cross the blood‑brain barrier, delivering therapeutic...
The BioPharm Brief: ADC Expansion, Early Breast Cancer, Biosimilar Momentum
Regeneron announced a collaboration with Parabilis Medicines to enhance its antibody‑drug conjugate (ADC) platform using macrocyclic peptide technology. The FDA granted new neoadjuvant and adjuvant indications for AstraZeneca/Daiichi Sankyo’s Enhertu in HER2‑positive early breast cancer, citing a 53% reduction in...
How Advanced Analytics Partnerships Enhance the Biopharma Value Chain
Strategic biopharma alliances are increasingly embedding multimodal AI across the entire drug‑development pipeline. Partnerships leverage foundation models to sharpen biomarker discovery and patient selection for complex modalities such as antibody‑drug conjugates. Large‑scale genomic and clinical datasets enable virtual cell modeling...
The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion
AstraZeneca’s exploratory POTOMAC trial showed that combining its checkpoint inhibitor Imfinzi with BCG lowered early recurrence risk in patients with high‑risk non‑muscle‑invasive bladder cancer. At ASGCT 2026, Imviva presented early remission data from an allogeneic CAR‑T platform targeting lupus, hinting at...
Translational Intelligence: The CDMO's Unspoken Role in the ATMP Journey
Advanced therapy medicinal product (ATMP) developers face a critical translation gap between research‑stage processes and GMP‑compliant manufacturing, where the process itself becomes the product. This gap, not a funding issue, creates structural risk that can halt programs and deter investors....
Why AI Fails in Drug Development and How to Build Tools That Actually Deliver Real Value
Artificial intelligence can add real value to drug development only when it is tightly woven into existing expert‑led workflows and respects real‑world constraints. The authors, drawing on their experience at Intrepid Labs and Quotient Sciences, illustrate how AI tools that...
How Biologic Developers Are Using Optimized Platforms and Operations to Reach First-in-Human Trials
Catalent’s Emily Schirmer explains that early chemistry, manufacturing and controls (CMC) decisions and early engagement with a capable CDMO can dramatically shorten the path to first‑in‑human (FIH) trials. By evaluating the full supply chain—drug substance, product, fill‑finish and distribution—developers avoid...
AstraZeneca Reports Positive Phase 3 Data for Eneboparatide in Chronic Hypoparathyroidism
AstraZeneca announced that its investigational PTH‑1 receptor agonist eneboparatide met the primary endpoint in the Phase 3 CALYPSO trial, with 31.1% of patients achieving normalized serum calcium and independence from active vitamin D and high‑dose calcium supplements at 24 weeks. The placebo...
Multi-Attribute Methods Advance Analytics for Complex Therapeutic Development
At the 2026 AAPS National Biotechnology Conference, Agilent’s Dr. Ganesh Bala highlighted how multi‑attribute LC‑MS methods are reshaping analytics for complex bioconjugates such as antibody‑drug conjugates. He explained that peptide‑mapping‑based MAMs can simultaneously quantify critical quality attributes—including site‑specific conjugation and...
The BioPharm Brief: Precision Medicine Expansion Accelerates Autoimmune and Targeted Oncology Development
The FDA broadened Vyvgart’s label to cover all adult patients with generalized myasthenia gravis, removing the previous antibody‑status restriction. Zai Lab received fast‑track designation for its DLL3‑targeting antibody‑drug conjugate aimed at extrapulmonary neuroendocrine carcinomas, a disease with limited options. The...
Advancing Aseptic Precision: How Modern Filling Lines Elevate Sterility, Flexibility, and Throughput
Modern pharmaceutical filling lines are adopting isolator‑based, fully automated systems that integrate washing, sterilization, filling, sealing, and environmental control. Automation and AI‑driven analytics are boosting sterility assurance, reducing human intervention, and meeting stricter EU GMP Annex 1 and FDA requirements. These...
QP Essentials: Reducing Risk and Delays in EU and UK Trials
Clinical trial sponsors often encounter delays when shipping supplies to the EU and UK because Qualified Persons must certify each batch. Catalent’s webinar outlines the core QP responsibilities, highlights differences between EU and UK regulations, and offers practical steps such...
FDA Grants Fast Track Designation to Zai Lab’s DLL3-Targeting ADC for epNECs
Zai Lab’s DLL3‑targeting antibody‑drug conjugate zocilurtatug pelitecan received FDA Fast Track designation for extrapulmonary neuroendocrine carcinomas (epNECs). Early‑stage data showed a 38.2% objective response rate in heavily pre‑treated patients, indicating meaningful antitumor activity. The designation promises more frequent FDA interactions,...
The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies
Harbour BioMed has secured FDA clearance to start a Phase I trial of its B7H4×CD3 bispecific antibody, HBM7004, in patients with advanced solid tumors. Merck published a scalable biocatalytic process for its oral PCSK9 inhibitor, enlicitide decanoate, showcasing a new route...
Addressing Manufacturing and Access Barriers in Advanced Therapeutics
Advanced cell and gene therapies are moving from research to commercial markets, but their complex manufacturing creates variability that delays patient access. Industry leaders are deploying process analytical technologies (PAT) and artificial intelligence (AI) to gain real‑time insight and predictive...
Harbour BioMed Gains FDA Clearance for First-in-Human Study of B7H4xCD3 Bispecific Antibody HBM7004
Harbour BioMed announced FDA IND clearance to launch a Phase I first‑in‑human study of its bispecific antibody HBM7004, which targets B7H4 and CD3 in advanced solid tumors. The trial will assess safety, tolerability, pharmacokinetics and early anti‑tumor activity across multiple cancer...
Merck Advances Scalable Manufacturing for Oral PCSK9 Therapy
Merck has published a landmark study in Science describing a scalable biocatalytic synthesis platform for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The enzyme‑driven process enables selective peptide fragment formation, coupling, macrocyclization and uses crystallization‑based purification, aiming to reduce reliance...
The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine
Aptevo Therapeutics reported an 87% clinical benefit rate and 81% remission in its Phase 1b AML RAINIER study, combining mipletamig with venetoclax and azacitidine. Entrada Therapeutics disclosed positive Phase 1/2 data for ENTR‑601‑44, showing functional gains and increased dystrophin in Duchenne patients...
Stem Cell-Derived Islet Therapies Target Type 1 Diabetes Challenges
Sana Biotechnology is leveraging hypoimmune cell engineering to create allogeneic, stem‑cell‑derived pancreatic islet‑like cells that can evade both adaptive and innate immune attacks. The company aims to deliver a single intramuscular injection that restores normal blood‑sugar control for type 1 diabetes...
Aptevo Reports Strong Remission Data in Frontline AML Trial as RAINIER Study Advances Toward Phase 2
Aptevo Therapeutics disclosed Phase 1b data from its RAINIER trial, showing mipletamig combined with venetoclax and azacitidine achieved an 87% clinical benefit rate and an 81% composite remission rate in 31 frontline AML patients. The regimen produced a 65% complete remission...
Funding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer Immunotherapies
Kanvas Biosciences and LTZ Therapeutics announced a combined $86 million financing round to accelerate next‑generation cancer immunotherapies. Kanvas closed a $48 million Series A to push its microbiome‑based platform and the lead candidate KAN‑001 toward clinical trials. LTZ secured $38 million to expand its...
The BioPharm Brief: Precision, Immunotherapy, Expansion
Madrigal Pharmaceuticals is licensing Arrowhead’s RNA‑interference candidate ARO‑PNPLA3 to broaden its precision‑medicine pipeline for metabolic dysfunction‑associated steatohepatitis (MASH). LTZ Therapeutics secured $38 million to push forward myeloid‑engager immunotherapies that activate innate immune cells against cancer. Amgen and Eli Lilly announced major U.S....
LTZ Therapeutics Secures $38M to Advance Myeloid Engager Immunotherapy Pipeline
LTZ Therapeutics announced an oversubscribed $38 million financing round led by GL Ventures, bringing its total capital to roughly $130 million since 2022. The funds will propel the Universal Myeloid Cell Engager (U‑MCE) platform, supporting the Phase 1 trial of lead bispecific antibody...
The BioPharm Brief: Breakthrough Biologics and Long-Term Wins in IBD and Beyond
Viridian Therapeutics reported positive Phase III REVEAL‑2 data for veligrotug (VRDN‑001) in chronic thyroid eye disease, showing statistically significant reductions in proptosis and higher overall response rates. Eli Lilly presented four‑year long‑term results for mirikizumab (Omvoh) in ulcerative colitis, with a substantial...
Viridian Reports Positive Phase III REVEAL-2 Data for Elegrobart in Chronic Thyroid Eye Disease
Viridian Therapeutics announced that its subcutaneous IGF‑1R antibody elegrobart met the primary endpoint in the phase 3 REVEAL‑2 trial for chronic thyroid eye disease (TED). Patients receiving the drug every four or eight weeks showed 50‑54% proptosis responder rates and 55‑61%...
Phase 3 FUZION Data Show Guselkumab Benefit in Perianal Fistulizing Crohn Disease
Late‑breaking Phase 3 FUZION data presented at DDW 2026 show that guselkumab significantly improves combined fistula remission in adults with perianal fistulizing Crohn disease. At 24 weeks, remission rates were 28.3% with 100 mg every eight weeks and 27.0% with 200 mg every four weeks,...
AAPS NBC 2026 To Highlight Predictive Tools in Drug Discovery with Opening Plenary
The AAPS National Biotechnology Conference 2026 will open with a plenary by Johns Hopkins professor Thomas Hartung, focusing on artificial intelligence and new‑approach methods (NAMs) that enhance predictive toxicology and human‑relevant models. Hartung will detail how AI‑driven in‑vitro systems, organoids...
Choosing the Right CDMO for Long-Term Stability
Biotech firms must scrutinize contract development and manufacturing organizations (CDMOs) before committing to multi‑year projects. Dr. Patrick Meyer of Rentschler Biopharma outlines criteria such as transparent communication, accurate timelines, and a proven commercialization record. Technical expertise and a resilient supply chain...
The Biopharm Brief: Microbiome Fast Track, Leo Pharma Gene Therapy Deal, AAV Automation Advances
The FDA has awarded Fast Track designation to a live biotherapeutic aimed at restoring gut microbiota in moderate‑to‑severe ulcerative colitis, accelerating its development path. Leo Pharma is buying Replay’s gene‑therapy program to broaden its rare‑dermatology portfolio, marking a shift toward...
Ensorcell Debuts VersaWeld Platform, Wins Best New Product at INTERPHEX 2026
Ensorcell introduced the VersaWeld sterile tube welding platform at INTERPHEX 2026, marking its entry into cell and gene therapy (CGT) manufacturing equipment. The system automates thermoplastic tubing welding in closed‑system environments, delivering consistent weld integrity across multiple tube sizes and materials...
Microbiome-Based Therapy Gains FDA Fast Track in Ulcerative Colitis
Belgium‑based MRM Health announced that its investigational microbiome‑based therapy MH002 has been granted FDA fast track designation for mild‑to‑moderate ulcerative colitis. MH002 is a live biotherapeutic composed of six defined commensal bacterial strains designed to restore gut microbial balance and...